TY - JOUR
KW - Adult
KW - Analgesics, Opioid/therapeutic use
KW - Buprenorphine/therapeutic use
KW - Feasibility Studies
KW - Female
KW - Humans
KW - Infant, Newborn
KW - intersectoral collaboration
KW - Methadone/therapeutic use
KW - Opiate Substitution Treatment/methods
KW - Opioid-Related Disorders/drug therapy
KW - Perinatal Care/methods
KW - Pregnancy
KW - Program Development/statistics & numerical data
KW - Retrospective Studies
KW - Young Adult
KW - buprenorphine
KW - collaborative care
KW - opioid use disorder
AU - Leena Mittal
AU - Joji Suzuki
A1 - 
AB - BACKGROUND: Medication-assisted treatment with buprenorphine or methadone is recommended for pregnant patients with opioid use disorders (OUDs) to minimize adverse maternal and neonatal outcomes. Collaborative care approaches have been successfully utilized with office-based opioid treatment with buprenorphine in primary care settings, but research is significantly limited in the obstetric setting. Our aim with this study is to demonstrate the feasibility of a collaborative care model for pregnant patients with opioid use disorder. METHODS: This is a case series of 16 pregnancies in 14 women initiated on office-based opioid treatment with buprenorphine in a perinatal mental health service embedded in 2 obstetric clinics. Patients are treated by a psychiatrist alongside their prenatal care provider and followed for up to 6 months postpartum and referred to ongoing substance abuse treatment to a community prescriber. RESULTS: The average age of the patients was 30.3 years, and an average gestational age of 23.6 weeks at the time of referral. Treatment continued until delivery in 15 (93.8%) pregnancies, with an average duration of treatment of 14.5 weeks. The majority (60%) had a cesarean delivery. Twelve (80%) infants were admitted to the Neonatal Intensive Care Unit (NICU) for monitoring or treatment of neonatal abstinence syndrome, 14 (87.5%) patients continued or resumed treatment with buprenorphine postpartum at the time of discharge from our program, and 13 (81.3%) were referred to a community prescriber. CONCLUSIONS: A collaborative care approach to buprenorphine treatment is feasible during pregnancy. Further research is needed to improve the treatment of OUD during pregnancy.
AD - a Brigham and Women's Hospital , Boston , Massachusetts , USA.; b Harvard Medical School , Boston , Massachusetts , USA.; a Brigham and Women's Hospital , Boston , Massachusetts , USA.; b Harvard Medical School , Boston , Massachusetts , USA.
BT - Substance abuse
C5 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
CP - 3
CY - United States
DO - 10.1080/08897077.2015.1129525
IS - 3
JF - Substance abuse
LA - eng
M1 - Journal Article
N2 - BACKGROUND: Medication-assisted treatment with buprenorphine or methadone is recommended for pregnant patients with opioid use disorders (OUDs) to minimize adverse maternal and neonatal outcomes. Collaborative care approaches have been successfully utilized with office-based opioid treatment with buprenorphine in primary care settings, but research is significantly limited in the obstetric setting. Our aim with this study is to demonstrate the feasibility of a collaborative care model for pregnant patients with opioid use disorder. METHODS: This is a case series of 16 pregnancies in 14 women initiated on office-based opioid treatment with buprenorphine in a perinatal mental health service embedded in 2 obstetric clinics. Patients are treated by a psychiatrist alongside their prenatal care provider and followed for up to 6 months postpartum and referred to ongoing substance abuse treatment to a community prescriber. RESULTS: The average age of the patients was 30.3 years, and an average gestational age of 23.6 weeks at the time of referral. Treatment continued until delivery in 15 (93.8%) pregnancies, with an average duration of treatment of 14.5 weeks. The majority (60%) had a cesarean delivery. Twelve (80%) infants were admitted to the Neonatal Intensive Care Unit (NICU) for monitoring or treatment of neonatal abstinence syndrome, 14 (87.5%) patients continued or resumed treatment with buprenorphine postpartum at the time of discharge from our program, and 13 (81.3%) were referred to a community prescriber. CONCLUSIONS: A collaborative care approach to buprenorphine treatment is feasible during pregnancy. Further research is needed to improve the treatment of OUD during pregnancy.
PP - United States
PY - 2017
SN - 1547-0164; 0889-7077
SP - 261
EP - 264
EP - 
T1 - Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy
T2 - Substance abuse
TI - Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy
U1 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
U2 - 26672650
U3 - 10.1080/08897077.2015.1129525
VL - 38
VO - 1547-0164; 0889-7077
Y1 - 2017
Y2 - Jul-Sep
ER -